Plain-English translation of NCT06341907 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new approach for people with epithelial ovarian cancer who have had surgery. Researchers will create a personalized based on your specific tumor's genetic makeup, then give it to you as a series of injections alongside your regular chemotherapy or other standard care. The goal is to help your immune system recognize and attack any remaining cancer cells that might lead to recurrence.
Even after surgery removes the visible tumor, sometimes tiny cancer cells remain in the body that can't be detected by standard blood tests or imaging—but can be found through specialized genetic testing. This trial exists to see whether the medication can help your immune system find and destroy those hidden cells before they grow back into a full recurrence.
You likely qualify if…
You likely don't qualify if…
First, researchers will analyze your tumor tissue to identify the specific mutations unique to your cancer and create a personalized vaccine. You will receive injections of this custom vaccine in two rounds: the first round involves five injections over three weeks (on days 1, 4, 8, 15, and 22), and the second round involves two injections about a month later (on days 54 and 84). Throughout and after treatment, you'll have regular blood tests, imaging scans, and checkups to monitor for any signs of cancer returning and to check how well your body is tolerating the treatment.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China